JP2010528583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528583A5 JP2010528583A5 JP2009519711A JP2009519711A JP2010528583A5 JP 2010528583 A5 JP2010528583 A5 JP 2010528583A5 JP 2009519711 A JP2009519711 A JP 2009519711A JP 2009519711 A JP2009519711 A JP 2009519711A JP 2010528583 A5 JP2010528583 A5 JP 2010528583A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- fragment
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims 94
- 125000003275 alpha amino acid group Chemical group 0.000 claims 90
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 19
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 19
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 15
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 12
- 239000000178 monomer Substances 0.000 claims 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 10
- 206010002022 amyloidosis Diseases 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 241000288906 Primates Species 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 7
- 230000001149 cognitive effect Effects 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 6
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 6
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 6
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 6
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- 230000007087 memory ability Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 241000282412 Homo Species 0.000 claims 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 4
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 claims 4
- GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 239000000835 fiber Substances 0.000 claims 4
- 108010073025 phenylalanylphenylalanine Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 238000004220 aggregation Methods 0.000 claims 3
- 210000001124 body fluid Anatomy 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000009260 cross reactivity Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 claims 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims 2
- 208000023769 AA amyloidosis Diseases 0.000 claims 2
- 208000018282 ACys amyloidosis Diseases 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 102000001049 Amyloid Human genes 0.000 claims 2
- 108010094108 Amyloid Proteins 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims 2
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010039811 Secondary amyloidosis Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 102000013498 tau Proteins Human genes 0.000 claims 2
- 108010026424 tau Proteins Proteins 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims 1
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical compound N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 claims 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 1
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 229940121773 Secretase inhibitor Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003942 amyloidogenic effect Effects 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims 1
- 229960004633 pirenzepine Drugs 0.000 claims 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94328907P | 2007-06-11 | 2007-06-11 | |
| US94349907P | 2007-06-12 | 2007-06-12 | |
| PCT/US2007/073504 WO2008011348A2 (en) | 2006-07-14 | 2007-07-13 | Humanized antibody against amyloid beta |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014026254A Division JP6076274B2 (ja) | 2007-06-11 | 2014-02-14 | アミロイドβに対するヒト化抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528583A JP2010528583A (ja) | 2010-08-26 |
| JP2010528583A5 true JP2010528583A5 (enExample) | 2010-10-07 |
Family
ID=42767991
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519711A Withdrawn JP2010528583A (ja) | 2007-06-11 | 2007-07-13 | アミロイドβに対するヒト化抗体 |
| JP2014026254A Active JP6076274B2 (ja) | 2007-06-11 | 2014-02-14 | アミロイドβに対するヒト化抗体 |
| JP2016160107A Pending JP2016202186A (ja) | 2007-06-11 | 2016-08-17 | アミロイドβに対するヒト化抗体 |
| JP2018155243A Pending JP2019004892A (ja) | 2007-06-11 | 2018-08-22 | アミロイドβに対するヒト化抗体 |
| JP2020124869A Pending JP2021006025A (ja) | 2007-06-11 | 2020-07-22 | アミロイドβに対するヒト化抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014026254A Active JP6076274B2 (ja) | 2007-06-11 | 2014-02-14 | アミロイドβに対するヒト化抗体 |
| JP2016160107A Pending JP2016202186A (ja) | 2007-06-11 | 2016-08-17 | アミロイドβに対するヒト化抗体 |
| JP2018155243A Pending JP2019004892A (ja) | 2007-06-11 | 2018-08-22 | アミロイドβに対するヒト化抗体 |
| JP2020124869A Pending JP2021006025A (ja) | 2007-06-11 | 2020-07-22 | アミロイドβに対するヒト化抗体 |
Country Status (1)
| Country | Link |
|---|---|
| JP (5) | JP2010528583A (enExample) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT396939B (de) * | 1990-05-29 | 1993-12-27 | Alois Dipl Ing Dr Jungbauer | Komplexes virales antigen von hiv-1 bindendes rekombinantes protein |
| US5837822A (en) * | 1992-01-27 | 1998-11-17 | Icos Corporation | Humanized antibodies specific for ICAM related protein |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| AU784312B2 (en) * | 1999-11-29 | 2006-03-09 | Bellus Health (International) Limited | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| KR100767146B1 (ko) * | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| DK1461359T3 (da) * | 2002-01-18 | 2007-07-09 | Pf Medicament | Hidtil ukendte anti-IGF-IR-antistoffer og anvendelser deraf |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| AU2005269940A1 (en) * | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta) |
| TWI380996B (zh) * | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| WO2006066171A1 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid βετα antibodies for use in improving cognition |
| EA201100177A1 (ru) * | 2005-06-17 | 2011-06-30 | Элан Фарма Интернэшнл Лимитед | СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ |
| SG10201706600VA (en) * | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
-
2007
- 2007-07-13 JP JP2009519711A patent/JP2010528583A/ja not_active Withdrawn
-
2014
- 2014-02-14 JP JP2014026254A patent/JP6076274B2/ja active Active
-
2016
- 2016-08-17 JP JP2016160107A patent/JP2016202186A/ja active Pending
-
2018
- 2018-08-22 JP JP2018155243A patent/JP2019004892A/ja active Pending
-
2020
- 2020-07-22 JP JP2020124869A patent/JP2021006025A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505415A5 (enExample) | ||
| CA2853531C (en) | Humanized antibodies that recognize alpha-synuclein | |
| JP6342333B2 (ja) | α−シヌクレインを認識するヒト化抗体 | |
| KR100767146B1 (ko) | Ａβ 펩티드를 격리시키는 인간화 항체 | |
| CN103339146B (zh) | 人抗tau抗体 | |
| RU2009104769A (ru) | Гуманизированное антитело к амилоиду бета | |
| JP2010530744A5 (enExample) | ||
| RU2010100342A (ru) | Гуманизированные антитела к амилоиду бета | |
| MX2008012223A (es) | Anticuerpos selectivos de protofibrilo mejorados y su uso. | |
| JP2008523815A (ja) | 認知の改善における使用のためのヒト化アミロイドβ抗体 | |
| US11440953B2 (en) | Anti-abeta antibodies | |
| RU2013115283A (ru) | Гуманизированное антитело к амилоиду бета | |
| JP2010528583A5 (enExample) | ||
| KR102655944B1 (ko) | 항-아밀로이드 베타 항체 및 이의 사용 방법 | |
| WO2025228316A1 (en) | Anti-n3pglu amyloid beta antibodies and uses thereof | |
| WO2025228315A1 (en) | Anti-n3pglu amyloid beta antibodies and uses thereof | |
| WO2025047850A1 (ja) | 神経変性疾患の治療剤 | |
| WO2024157085A1 (en) | Methods of treating neurological disorders with anti-abeta antibodies |